Q2 Earnings Season Breaks Its Own Rules as Share-Price Reactions Decouple From Results
Historic reporting volume is producing increasingly random post-print moves, while AbbVie's neuroscience franchise emerges as a $12.7 billion sleeper business
Analysts flag a widening disconnect between reported fundamentals and share-price reactions during a historic Q2 earnings season, complicating event-driven positioning. AbbVie's guidance for $12.7 billion in neuroscience sales this year is a case study in fundamentals the market has been slow to price.